SQNM - news 2.10. - 500 Beiträge pro Seite

[ToeJam]

Schätze heute gehts erst richtig los:
-----

10-02-2000

Incyte and SEQUENOM to Create World`s
Largest Set Of Validated SNP Assays for
Genetic Research

PALO ALTO, Calif., and SAN DIEGO, Oct. 2 /PRNewswire/ -- Incyte Genomics, Inc. (Nasdaq: INCY -
news), the leading genomic information company, and SEQUENOM, Inc. (Nasdaq: SQNM - news), the
leading provider of SNP analysis strategies and technology, today announced a collaboration
whereby the two companies will work together to create high-quality validated SNP assays for use in
genetics research. SNPs, single nucleotide polymorphisms, are genetic variations between individuals
and are important factors in determining disease susceptibility and individual response to medication.
Financial terms were not disclosed.

Incyte has developed a proprietary state-of-the-art polymorphism detection algorithm to identify SNPs
from its LifeSeq® Gold database, the world`s most comprehensive collection of genes. LifeSeq Gold
contains over 120,000 transcribed genes, of which approximately half are proprietary to Incyte and
therefore unique. Incyte`s SNPs are particularly valuable because they are located within genes and
are likely to code for changes in gene structure and protein sequence. SNPs that alter a gene`s
function are extraordinarily useful to researchers in understanding the molecular basis for disease
and individual response to medication.

Under the terms of the agreement, Incyte will license SNPs to SEQUENOM for analysis and validation
using SEQUENOM`s MassARRAY(TM) technology, which is capable of analyzing hundreds of
samples in a single reaction. In return, SEQUENOM will provide Incyte with access to its MassARRAY
technology and proprietary marker validation strategies. SEQUENOM will use the validated SNP
information to develop and market 100,000 SNP assays, or tests for genetic markers. SEQUENOM
plans to make these validated SNP assays available worldwide to genetic researchers, and will
enable them to better identify the SNPs involved in disease, and to predict associations between
SNPs and individual response to medication.

Further to the agreement, SEQUENOM will screen the SNPs against its in-house reference human
DNA bank, which contains 16,000 samples carefully selected to represent the general population.
SEQUENOM will provide allele frequencies in four distinct ethnic groups and validate the 100,000
gene-based SNPs for their medical utility using a proprietary and proven population genetics
approach. SEQUENOM and Incyte have agreed to jointly commercialize the resulting intellectual
property and expect to form partnership programs for downstream product development.

Researchers using these SNP assays can access Incyte`s web site to purchase gene sequence and
annotation information and clones using LifeSeq® Gene-by-Gene. This ``click through`` mechanism
enables researchers to quickly and easily obtain information about Incyte`s proprietary genes and to
order clones and other products for conducting further research.

``We are pleased to collaborate with SEQUENOM, a proven leader in the area of SNP analysis, to
validate pharmaceutically relevant SNPs and develop assays,`` said Roy A. Whitfield, Chief Executive
Officer of Incyte. ``We have focused our SNP discovery efforts on genes that are important in drug
metabolism and those that are common drug targets. By understanding the SNPs within candidate
genes in therapeutic areas and in drug metabolism response, researchers will be able to better
understand individual susceptibility to disease, and response drugs.``

``This collaboration represents the largest commercial undertaking of its kind. Together, Incyte and
SEQUENOM are pioneering the next phase of genomics through large-scale validation of the medical
utility of genetic markers,`` said Toni Schuh, Ph.D., SEQUENOM`s President and CEO. ``By combining
Incyte`s high value gene-based SNPs with SEQUENOM`s proprietary SNP validation platform and
population genetics approach, Incyte and SEQUENOM will offer highly valuable knowledge to a broad
customer base and are positioned to lead the race in generating intellectual property covering the
use of genetic markers.``

SEQUENOM is a post-genomics company translating information generated from the map of the
human genome into practical applications by offering a comprehensive genotyping technology to
determine the medical relevance of genetic variations. SEQUENOM`s distinct competitive advantage
is a SNP analysis solution consisting of its highly accurate and robust MassARRAY system, an
automated assay development process and assay database, the ability to analyze hundreds of
samples in a single reaction and a proven health-based concept for genetic marker validation. As a
leader in SNP analysis, SEQUENOM offers its powerful technology to customers in diagnostics,
pharmacogenomics, drug development and agricultural biotechnology, while using the MassARRAY
technology with a novel scientific strategy for in-house programs to identify the medical utility of
SNPs. SEQUENOM is headquartered in San Diego, California with offices in Hamburg, Germany and
Boston, Massachusetts.

Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies
designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets
genomic databases and partnership programs, genomic data management software,
microarray-based gene expression services, related reagents and services. These products,
programs and services assist pharmaceutical and biotechnology researchers with all phases of drug
discovery and development including gene discovery, understanding disease pathways, identifying
new disease targets and the discovery and correlation of gene sequence variation to disease. For
more information, visit Incyte`s web site at http://www.incyte.com.

Except for the historical information contained herein, the matters set forth in this press release,
including statements as to the value of SNPs for use in genetics research, the use of SNPs to
understand the molecular basis for disease and individual response to medication, the worldwide
availability of validated SNP assays, the joint commercialization of intellectual property, the formation
of partnership programs, and the ability to develop 100,000 SNP assays, are forward-looking
statements within the meaning of the ``safe harbor`` provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may
cause actual results to differ materially, including, the utilization of SNP assays in pharmaceutical
research and development; the impact of technological advances and competition; changes in the
business plans of Incyte and SEQUENOM; and other risks detailed from time to time in Incyte and
SEQUENOM`s SEC reports, including SEQUENOM`s Annual Report on Form 10-K for the year ended
December 31, 1999 and Incyte and SEQUENOM`s Quarterly Reports on Form 10-Q for the quarter
ended June 30, 2000. Incyte and SEQUENOM disclaim any intent or obligation to update these
forward-looking statements.

SOURCE: Incyte Genomics, Inc.; SEQUENOM, Inc.

[Endless]

Hallo!!

Ich denke nicht das diese NEWS dem Kurs jetzt Kräftig was bringt!! Kann mich natürlich auch täuschen,
aber solche ähnlichen Neuigkeiten gab es in letzter Zeit des öfteren, und die Aktie reagierte nicht nachhaltig
darauf!!
Von charttechnischen sieht es allerdings nicht so gut aus für einen guten Anstieg!! Ich denke zwar das wir die
50$ diese oder nächste Woche sehen, aber für heute und vielleicht auch morgen schätze ich, daß es etwas
schwächer wird!!
Ich hoffe natürlich auch das es schnell hochgeht, jedoch wäre mir, mit "Zwischenpausen", ein Etappenanstieg
lieber, da dieser etwas sicherer ist!!


Gruß,

Endless

[ToeJam]

@endless:

Ich halte diese news für wesentlich (!) bedeutender als die Meldung vom Freitag. Aber ich kann
mich natürlich irren und es kommt kurzfristig zu Gewinnmitnahmen. Was solls; bin langfristig
orientiert.

[Endless]

Hallo!!

Ich hoffe genau wie ihr das es hoch geht!! Meine Befürchtung sind ebenfalls Gewinnmitnahmen!!

Gruß,

Endless

[ACG]

Hi Leute !
Ich schätze wen das Börsenklima wieder besser wird
,dann Ist "Sequenom"ganz ganz scnell bei 1** Euro.
Schneller als ihr alle denkt.

[Endless]

HEY LEUTE!!!!!!!

SQNM vorbörslich bei über 44$!!!!!!!!!!!!!!!!!!!!!!!!


Gruß,

Endless

[ToeJam]

Die 44 sind Geld. Briefkurs gibts noch nicht :-)